Breakthrough Therapy (BT) Designation Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4141022
- 156 Pages
- December 2020
- Healthcare
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Breakthrough Therapy (BT) Designation market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Breakthrough Therapy (BT) Designation market segmented into
Oncology
Infectious Diseases
Rare Diseases
Autoimmune Diseases
Pulmonary Diseases
Neurological Disorders
Others
Based on the end-use, the global Breakthrough Therapy (BT) Designation market classified into
Hospital
Clinic
Research Institute
Laboratories
Based on geography, the global Breakthrough Therapy (BT) Designation market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Roche
Abbvie
Novartis International AG
Janssen
BMS
Eli Lilly
Gilead
Sanofi
Regeneron
Acadia
Boehringer Ingelheim
Amgen
AstraZeneca
GlaxoSmithKline
Vertex
Alexion
Merck
Jazz Pharmaceuticals
Exelixis
Eisai
Takeda
Pfizer
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL BREAKTHROUGH THERAPY (BT) DESIGNATION INDUSTRY
2.1 Summary about Breakthrough Therapy (BT) Designation Industry
2.2 Breakthrough Therapy (BT) Designation Market Trends
2.2.1 Breakthrough Therapy (BT) Designation Production & Consumption Trends
2.2.2 Breakthrough Therapy (BT) Designation Demand Structure Trends
2.3 Breakthrough Therapy (BT) Designation Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Oncology
4.2.2 Infectious Diseases
4.2.3 Rare Diseases
4.2.4 Autoimmune Diseases
4.2.5 Pulmonary Diseases
4.2.6 Neurological Disorders
4.2.7 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Research Institute
4.3.4 Laboratories
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Oncology
5.2.2 Infectious Diseases
5.2.3 Rare Diseases
5.2.4 Autoimmune Diseases
5.2.5 Pulmonary Diseases
5.2.6 Neurological Disorders
5.2.7 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Research Institute
5.3.4 Laboratories
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Oncology
6.2.2 Infectious Diseases
6.2.3 Rare Diseases
6.2.4 Autoimmune Diseases
6.2.5 Pulmonary Diseases
6.2.6 Neurological Disorders
6.2.7 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Research Institute
6.3.4 Laboratories
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Oncology
7.2.2 Infectious Diseases
7.2.3 Rare Diseases
7.2.4 Autoimmune Diseases
7.2.5 Pulmonary Diseases
7.2.6 Neurological Disorders
7.2.7 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Research Institute
7.3.4 Laboratories
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Oncology
8.2.2 Infectious Diseases
8.2.3 Rare Diseases
8.2.4 Autoimmune Diseases
8.2.5 Pulmonary Diseases
8.2.6 Neurological Disorders
8.2.7 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Research Institute
8.3.4 Laboratories
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Oncology
9.2.2 Infectious Diseases
9.2.3 Rare Diseases
9.2.4 Autoimmune Diseases
9.2.5 Pulmonary Diseases
9.2.6 Neurological Disorders
9.2.7 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Research Institute
9.3.4 Laboratories
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Roche
10.1.2 Abbvie
10.1.3 Novartis International AG
10.1.4 Janssen
10.1.5 BMS
10.1.6 Eli Lilly
10.1.7 Gilead
10.1.8 Sanofi
10.1.9 Regeneron
10.1.10 Acadia
10.1.11 Boehringer Ingelheim
10.1.12 Amgen
10.1.13 AstraZeneca
10.1.14 GlaxoSmithKline
10.1.15 Vertex
10.1.16 Alexion
10.1.17 Merck
10.1.18 Jazz Pharmaceuticals
10.1.19 Exelixis
10.1.20 Eisai
10.1.21 Takeda
10.1.22 Pfizer
10.2 Breakthrough Therapy (BT) Designation Sales Date of Major Players (2017-2020e)
10.2.1 Roche
10.2.2 Abbvie
10.2.3 Novartis International AG
10.2.4 Janssen
10.2.5 BMS
10.2.6 Eli Lilly
10.2.7 Gilead
10.2.8 Sanofi
10.2.9 Regeneron
10.2.10 Acadia
10.2.11 Boehringer Ingelheim
10.2.12 Amgen
10.2.13 AstraZeneca
10.2.14 GlaxoSmithKline
10.2.15 Vertex
10.2.16 Alexion
10.2.17 Merck
10.2.18 Jazz Pharmaceuticals
10.2.19 Exelixis
10.2.20 Eisai
10.2.21 Takeda
10.2.22 Pfizer
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
Table Breakthrough Therapy (BT) Designation Product Type Overview
Table Breakthrough Therapy (BT) Designation Product Type Market Share List
Table Breakthrough Therapy (BT) Designation Product Type of Major Players
Table Brief Introduction of Roche
Table Brief Introduction of Abbvie
Table Brief Introduction of Novartis International AG
Table Brief Introduction of Janssen
Table Brief Introduction of BMS
Table Brief Introduction of Eli Lilly
Table Brief Introduction of Gilead
Table Brief Introduction of Sanofi
Table Brief Introduction of Regeneron
Table Brief Introduction of Acadia
Table Brief Introduction of Boehringer Ingelheim
Table Brief Introduction of Amgen
Table Brief Introduction of AstraZeneca
Table Brief Introduction of GlaxoSmithKline
Table Brief Introduction of Vertex
Table Brief Introduction of Alexion
Table Brief Introduction of Merck
Table Brief Introduction of Jazz Pharmaceuticals
Table Brief Introduction of Exelixis
Table Brief Introduction of Eisai
Table Brief Introduction of Takeda
Table Brief Introduction of Pfizer
Table Products & Services of Roche
Table Products & Services of Abbvie
Table Products & Services of Novartis International AG
Table Products & Services of Janssen
Table Products & Services of BMS
Table Products & Services of Eli Lilly
Table Products & Services of Gilead
Table Products & Services of Sanofi
Table Products & Services of Regeneron
Table Products & Services of Acadia
Table Products & Services of Boehringer Ingelheim
Table Products & Services of Amgen
Table Products & Services of AstraZeneca
Table Products & Services of GlaxoSmithKline
Table Products & Services of Vertex
Table Products & Services of Alexion
Table Products & Services of Merck
Table Products & Services of Jazz Pharmaceuticals
Table Products & Services of Exelixis
Table Products & Services of Eisai
Table Products & Services of Takeda
Table Products & Services of Pfizer
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Breakthrough Therapy (BT) Designation Market Forecast (Million USD) by Region 2021f-2026f
Table Global Breakthrough Therapy (BT) Designation Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Breakthrough Therapy (BT) Designation Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Breakthrough Therapy (BT) Designation Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
